Be part of the community helping to address colorectal cancer care
Do you want to be a part of something extraordinary? You and nearly one thousand other patients living with colorectal cancer have the opportunity to help the medical community to more deeply understand this disease. Learn more about our clinical study, BESPOKE CRC, which is currently enrolling patients living with colorectal cancer (CRC).
Enroll now to help the community learn more
Make a difference in the lives of individuals who, like you, are managing CRC. The BESPOKE CRC clinical study will examine participant data and blood samples to determine the effects of clinical outcomes upon incorporating the use of Signatera into stage II and III colorectal cancer treatment. Signatera Molecular Residual Disease (MRD) is a personalized surveillance test that is customized to reflect each patient’s unique set of tumor mutations.
The study will enroll at least one thousand patients. Natera and its collaborators will collect clinical utility and outcome data on enrolled patients for two years. Participants may receive up to $150 dollars for their time.
BESPOKE CRC trial design and patient qualification requirements
You may qualify if all of the following criteria apply
- You are a stage II or III colorectal cancer patient.
- Your doctor selected you to receive the Signatera test as part of your routine care.
- You are eligible for chemotherapy.
- You are able to tolerate blood draws from the arm.
- You are 18 years of age or older.
How is the Signatera test performed?
A one-time analysis of both blood and tissue determines your unique set of tumor mutations.
The test is custom-built and personalized for you
Signatera detects the presence or absence of cancer each time it is ordered as part of your routine follow-up blood tests.
With BESPOKE CRC, expect safety and simplicity.
- You will work with your doctor to set the schedule for blood draws, whether they are in clinic or at home.
- You will be asked to complete questionnaires throughout the two years of the study.
- You will work with your doctor to use Signatera test reports to help guide your care plan including, chemotherapy treatment and additional imaging scans.